Panel Discussion: From Proteinopathies to Pathways: The Next Wave of Disease-Modifying Therapies in AD & PD – Beyond Aβ, Tau & α-Synuclein
- How do we move beyond targeting amyloid, tau, and α-synuclein to intervene earlier in the disease cascade through pathways like neuroinflammation, lysosomal dysfunction, and mitochondrial stress?
- What evidence is now required to prove disease modification in the clinic, and how can diagnostic, target-engagement, and progression biomarkers be aligned to make this measurable and regulatory-credible?
- Where does precision neurology realistically stand today, and how far can patient subtyping and enrichment strategies go before regulatory and operational constraints take over?
- When do combination and mixed-modality approaches outperform single mechanisms, and how can they be designed to deliver more durable, scalable disease-modifying impact?